Tag
Weight loss
GLP-1 and metabolic peptides studied for weight and appetite.
Peptides
5-Amino-1MQ
NNMT enzyme inhibitor (small molecule)
5-Amino-1MQ is a small-molecule compound (not a peptide) that blocks an enzyme called NNMT, which has been linked to fat-tissue metabolism in animals. In mouse studies it was associated with reduced fat gain, but there is no published human data. It is a research chemical, and its effects and safety in people are unknown.
Read profileAOD-9604
Modified growth-hormone fragment (176-191)
AOD-9604 is a small fragment of human growth hormone that was investigated as a fat-loss agent. Early company-sponsored trials did not show meaningful weight loss beyond placebo, and it was not approved for that use. Today it is sold as a research chemical, and good human evidence for weight benefit is lacking.
Read profileAdipotide
Pro-apoptotic targeting peptide (prohibitin-targeting)
Adipotide is an experimental peptide that, in animals, targets the blood supply of fat tissue and triggers fat cells to die. In obese monkeys it produced weight loss, but it also raised safety concerns, including kidney effects. There are no established human trials supporting its use, and it is a research compound only.
Read profileCagrilintide
Long-acting amylin receptor agonist
Cagrilintide is an experimental long-acting medicine that mimics amylin, a hormone that works alongside insulin to reduce appetite and food intake. It is being studied for weight management, often combined with a GLP-1 drug, and human trials are ongoing. It is not approved, and long-term safety is not yet established.
Read profileCagrilintide + Semaglutide
Amylin agonist plus GLP-1 agonist combination
This is a combination of two appetite-acting medicines: cagrilintide (an amylin agonist) and semaglutide (a GLP-1 agonist). The idea is to target two different satiety pathways at once for greater weight loss. The combination has been studied in human trials with encouraging results, but it is not yet approved as a single product.
Read profileDulaglutide
GLP-1 receptor agonist
Dulaglutide is a once-weekly injectable medicine that mimics the gut hormone GLP-1 to help control blood sugar. It is FDA-approved for type 2 diabetes, and large human trials support its effects on blood sugar and cardiovascular risk. It is prescription-only.
Read profileEloralintide
Amylin receptor agonist
Eloralintide is an experimental amylin receptor agonist being developed for weight management. It is at an early stage of clinical development, and little human data has been published so far. It is not approved, and its efficacy and safety in people are not yet established.
Read profileLiraglutide
GLP-1 receptor agonist
Liraglutide is a daily injectable medicine that mimics the gut hormone GLP-1 to help control blood sugar and reduce appetite. It is FDA-approved for type 2 diabetes and for weight management, supported by large human trials. It is prescription-only.
Read profileMazdutide
Dual GLP-1 and glucagon receptor agonist
Mazdutide is an experimental medicine that activates two receptors (GLP-1 and glucagon) to lower blood sugar, reduce appetite, and increase energy use. It is in clinical development for weight management and diabetes, with trials concentrated in China. It is not approved, and long-term safety is not yet established.
Read profile